Title(s):
Assistant Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Anal Cancer, Bile Duct Cancer, Cancer of Unknown Primary, Carcinoid Syndrome, Carcinoid Tumors, Cholangiocarcinoma, Clinical Trials, Colon Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Cancers, Gastrointestinal Tumors, General Internal Medicine, Hepatocellular Cancer, Liver Cancer, Medical Oncology, Neuroendocrine Tumors, Pancreatic Cancer, Rectal Cancer, Small Bowel Cancer, Stomach Cancer
Education and Experience
Training
- Faculty of Medicine National University of Ireland (DUBLIN 2 )/ (2000)
Residencies
- The Johns Hopkins Hospital (Baltimore MD)/ Internal Medicine (2006)
- James Connolly Memorial Hospital (Dublin 15 )/ Internal Medicine (2002)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Medical Oncology (2009)
Certifications
- Medical Oncology, American Board of Internal Medicine (2008)
- Internal Medicine, American Board of Internal Medicine (2007)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Appointment Phone: 410-955-8964
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Sidney Kimmel Comprehensive Cancer Center
- Skip Viragh Center for Pancreas Cancer
Bio
Biography
Dr. Cosgrove aims to identify molecular biomarkers in cancer cells that can differentiate them from normal cells. These differences at the genetic and molecular level should allow us to develop drugs that will target only the cancer cells, and have minimal side effects on the patients normal cells. He is working closely with the gastrointestinal malignancies group to bring new drugs and combinations into clinical practice. The ultimate goal is to identify the best drug, or combination of drugs, for individual patients based upon their tumors genetic makeup. The same approach should also allow us to identify drugs that will not be effective against particular tumors, so ineffective therapy can be avoided.
Expertise
- Anal Cancer
- Bile Duct Cancer
- Cancer of Unknown Primary
- Carcinoid Syndrome
- Carcinoid Tumors
- Cholangiocarcinoma
- Clinical Trials
- Colon Cancer
- Colorectal Cancer
- Gallbladder Cancer
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Gastrointestinal Cancers
- Gastrointestinal Tumors
- General Internal Medicine
- Hepatocellular Cancer
- Liver Cancer
- Medical Oncology
- Neuroendocrine Tumors
- Pancreatic Cancer
- Rectal Cancer
- Small Bowel Cancer
- Stomach Cancer
Research
Research and Publications
Research Summary
Dr. Cosgroves research is focused on molecular changes in tumor cells, specifically within proliferation pathways such as MAPK and PISK/AKT. He is developing agents to target these pathways, and biomarkers to identify patients most likely to benefit from such agents.
Peer Reviewed Articles
1. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009;106(8):2835-40. PMCID: 2636736.
2. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, Buckhaults PJ, Park BH. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene. 2010;29(16):2337-45. PMCID: 3042798.
3. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg. 2011;15(11):2089-97. PMCID: Not supported through NIH funds.
4. Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biol Ther. 2011;11(3):358-67. PMCID: 3047087.
5. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011;108(43):17773-8. PMCID: 3203756.
6. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29(30):3960-7. PMCID: Not supported through NIH funds.
7. De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA, Jr. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69(2):415-24. PMCID: 3265723.
Book Chapters
1. Cosgrove D, Mouden M, Wise R. Chronic Obstructive Pulmonary Disease. In: Nilsson P, editor. Osler Handbook of Clinical Medicine, 2nd Edition. Philadelphia: Elsevier; 2006.
2. Cosgrove D, Donehower R. Adenocarcinoma of Unknown Primary [database on the Internet]. BMJ Group 2010 [cited 07/2010].
3. Cosgrove D, Park BH, Vogelstein B. Tumor Suppressor Genes. In: Waun Ki Hong, editor. Holland-Frei Cancer Medicine. Shelton: BC Decker/ American Association for Cancer Research; 2010. p. 86-102.
Reviews
1. Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 2008;8(8):733-40. PMCID: 2831175.
2. Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011;15(3):410-5.
3. Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012;16(4):874-81. PMCID: Not funded through NIH support.
Dr. Cosgroves research is focused on molecular changes in tumor cells, specifically within proliferation pathways such as MAPK and PISK/AKT. He is developing agents to target these pathways, and biomarkers to identify patients most likely to benefit from such agents.
Peer Reviewed Articles
1. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009;106(8):2835-40. PMCID: 2636736.
2. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, Buckhaults PJ, Park BH. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene. 2010;29(16):2337-45. PMCID: 3042798.
3. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg. 2011;15(11):2089-97. PMCID: Not supported through NIH funds.
4. Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biol Ther. 2011;11(3):358-67. PMCID: 3047087.
5. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011;108(43):17773-8. PMCID: 3203756.
6. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29(30):3960-7. PMCID: Not supported through NIH funds.
7. De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA, Jr. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69(2):415-24. PMCID: 3265723.
Book Chapters
1. Cosgrove D, Mouden M, Wise R. Chronic Obstructive Pulmonary Disease. In: Nilsson P, editor. Osler Handbook of Clinical Medicine, 2nd Edition. Philadelphia: Elsevier; 2006.
2. Cosgrove D, Donehower R. Adenocarcinoma of Unknown Primary [database on the Internet]. BMJ Group 2010 [cited 07/2010].
3. Cosgrove D, Park BH, Vogelstein B. Tumor Suppressor Genes. In: Waun Ki Hong, editor. Holland-Frei Cancer Medicine. Shelton: BC Decker/ American Association for Cancer Research; 2010. p. 86-102.
Reviews
1. Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 2008;8(8):733-40. PMCID: 2831175.
2. Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011;15(3):410-5.
3. Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012;16(4):874-81. PMCID: Not funded through NIH support.
Research Interests
- Hepatocellular carcinoma
- Biliary tract malignancies, as well as carcinoma of unknown primary site
- Gastrointestinal malignancies
More Info
Languages
- English
- German
Clinical Trials
- Phase I, gastrointestinal malignancies,hepatocellular carcinoma and biliary tract malignancies,carcinoma of unknown primary site.
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts